PORTO 2015
GENERAL ASSEMBLY, SCIENTIFIC CONFERENCES AND RELATED EVENTS
Instituto Português de Oncologia do Porto (IPO-Porto)
June 22nd-24th
OECI
INNOVATIVE
HIGH-QUALITY
CANCER CARE
THROUGH
COORDINATING
RESEARCH AND
EDUCATION
For the third time, the Directors of the European Cancer Centres will convene in Portugal, a country which, since the OECI’s foundation, has shown an extraordinary interest in our Organisation, as witnessed by the participation of all the cancer centres of the “Instituto Português de Oncologia do Porto FG, EPE” network in the OECI Accreditation and Designation Programme.

Each participating centre has received the OECI Certification and I hope that the Portuguese example, as in Italy, will be followed by other countries.

In this first year of my Presidency, I have been working on consolidating the OECI mandate and how our organisation can better respond to the needs of a rapidly changing society, patient needs, and those of our members. In recent years, the fast paced progress of science and technology has brought radical change to the very structure of our institutions, in order to meet the needs that personalised medicine now requires. There is an increasing need to work together to speed up the translation process, to give all our patients access to the best care and to reduce the unbearable burden of applied research that requires an increasing amount of human and financial investment.

The OECI membership should be seen as an investment that will increasingly become a two-way process in which the Institutes play a proactive and collaborative role. I am convinced that active involvement of the cancer institutes is our trump card if we want to qualify as THE European network of cancer institutions, formally recognized by the European Union. Let us not forget that the OECI is an inclusive Organisation and our wealth is represented by the diversities that exist amongst our member institutes.

The 2015 OECI Oncology Days programme sums up concisely how the process of OECI accreditation and designation, 5 years since the release of the first certification, helps to improve the organisational system, to secure the quality of our member institutes and to guarantee appropriate care to our patients, through multidisciplinarity and comprehensiveness. Personalised medicine will be challenging the current status quo in many of the processes in our cancer centres. We decided, therefore, to integrate those aspects and their impacts in the scientific session.

The 2015 Oncology Days is the 37th time that the Directors of European cancer centres meet. A solid example of the efforts made by the OECI and its members in supporting the role of a European coordinator, in order to reduce fragmentation, to improve the quality of care and research and to evaluate the cost-benefits linked with the application of new therapeutics, thereby avoiding unnecessary care approaches.

We thank the local Organisers and in particular the “Instituto Português de Oncologia do Porto FG, EPE”, which has made this event possible.
Dear Colleagues,

It is with enormous honor that we receive all of you in our institution and city. The Instituto Português de Oncologia do Porto is a standalone cancer Centre strategically committed with quality care and patient safety issues. The affiliation in OECI was very important in the past and we believe that in the future it will be the forum of excellence to represent cancer deliver organization in the European Community.

The crossroads of investigation and integration in care are always present in our mind and we hope that this meeting in Porto can strengthen the OECI vision for comprehensiveness.

We wish you a fruitful and happy journey in Porto.

[Signature]

Dr. Laranja Pontes
IPO-Porto President
Introduction to the OECI

The OECI is a non-governmental Organisation founded in Vienna, in 1979.

The primary objectives of its 70 Members are to reduce fragmentation and to give all European cancer patients the possibility of receiving the best available care. The OECI Members have established themselves in the innovation frontline by tailoring solutions to the individual patient, by gaining in efficiency and efficacy and with the potential to transform the way healthcare is delivered today.

To better achieve its goals, the Organisation works in close collaboration with the European Cancer Patients Coalition.

The OECI goals are achieved by promoting and strengthening the concept of Comprehensive Cancer Centres in Europe in order to improve quality in cancer care and translational research, as well as from an organisational viewpoint. In an effort to efficiently contribute towards an increase in the quality of care, 40% of all OECI Members are already participating in the OECI Accreditation/Designation programme.

In 2016, some of the already certified Centres will be re-visited in order to confirm their Designation status, according to the revised quality standards for comprehensive and multidisciplinary cancer care in European cancer centres, as published in the Second Edition of the OECI Accreditation and Designation User Manual. So far, 29 European wide, comprehensive and clinical cancer centres have taken part in the OECI Accreditation & Designation programme.

The OECI interacts with its members in the definition of tasks of international and common interest. The common goal is to facilitate member participation in European projects and programmes, to support training activities on forefront topics, which provides a sound basis for accelerated development of expertise and future collaborative work. This in turn attracts professionals and officers from across disciplines and ultimately underlines the value of multidisciplinary actions.

Giving the crucial role to pathology departments in oncology and in lieu of the expected “influx” of new markers and diagnostics, the OECI acts in close cooperation with the European Association for Cancer Research and the European Society of Pathology, in order to better disseminate the innovation process amongst its members and abroad. The EACR-OECI training course series in Luxembourg on “Precise Medicine”, and on “Molecular Pathology Approach to Cancer” in Amsterdam, are just two examples of the OECI efforts to promote the dissemination of innovation.

Managerial support is mainly organised through the President’s Office and the Central Office in Brussels, alongside the Liaison and Director’s Office in Genoa. You can find more information about the Organisation at www.oeci.eu. The dissemination of the OECI activities, reports, proceedings are also publicized through ecancermedicalscience, the Official OECI e-Journal at.
# The OECI Board

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Dominique de Valeriola</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>Past President</td>
<td>Wim H. van Harten</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Executive Secretary</td>
<td>Marco A. Pierotti</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Treasurer</td>
<td>José Maria Laranja Pontes</td>
<td>Porto, Portugal</td>
</tr>
<tr>
<td>Elected Member</td>
<td>Carlos Caldas</td>
<td>Cambridge, United Kingdom</td>
</tr>
<tr>
<td>Elected Member</td>
<td>Gunnar Sæter</td>
<td>Oslo, Norway</td>
</tr>
<tr>
<td>OECI Director</td>
<td>Claudio Lombardo</td>
<td>Genoa, Italy</td>
</tr>
<tr>
<td>OECI Central Office</td>
<td>Guy Storme</td>
<td>Brussels, Belgium</td>
</tr>
</tbody>
</table>

## Working Groups and Activities

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Leader</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accreditation and Designation</td>
<td>Mahasti Saghatchian</td>
<td>Paris, France</td>
</tr>
<tr>
<td>Biobanks and Molecular Pathobiology</td>
<td>Giorgio Stanta</td>
<td>Trieste, Italy</td>
</tr>
<tr>
<td>Cost - Benefit</td>
<td>Wim H. van Harten</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Palliative Care</td>
<td>Massimo Costantini</td>
<td>Reggio Emilia, Italy</td>
</tr>
<tr>
<td>EurocanPlatform</td>
<td>Ulrik Ringborg</td>
<td>Stockholm, Sweden</td>
</tr>
<tr>
<td>START-OECI</td>
<td>Lisa Licitra</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Communication and Dissemination</td>
<td>Gordon McVie</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td></td>
<td>Claudio Lombardo</td>
<td>Genoa, Italy</td>
</tr>
</tbody>
</table>
The OECI Quality Network

- OECI Members A&D certified
- OECI Members in the A&D process
- Other OECI Members
- Non-OECI Members in the A&D process
The OECI membership

Austria
- Comprehensive Cancer Center Graz, Graz
- Zentrum für Tumorerkrankungen Linz Onkologisches Leitspital für Oberösterreich, Linz
- Comprehensive Cancer Center Vienna, Vienna

Belgium
- Institut Jules Bordet (IJB), Brussels
- Kankercentrum Brussel, Brussels
- Institut Roi Albert II, Brussels

Czech Republic
- Masarykův onkologický ústav, Brno
- Institut biostatistiky a analýz Lékářské a Prírodovedecké fakulty Masarykovy university, Brno

Denmark
- Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen

Estonia
- Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin

Finland
- HYKS Syöpäkeskus Helsinki University, Helsinki

France
- Gustave Roussy, Villejuif
- Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg
- Institut Curie, Paris
- Centre Henri Becquerel, Rouen
- Centre Leon Berard, Lyon
- Centre Alexis Vautrin, Nancy

Germany
- Universitäts KrebsCentrum Dresden, Dresden
- Charité Comprehensive Cancer Centre, Berlin
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg

Hungary
- Országos Onkológiai Intézet, Budapest
- National Koranyi Institute of TB and Pulmonology, Budapest

Italy
- Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano
- Istituto Europeo di Oncologia, Milan
- Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS, Reggio Emilia
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan
- Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro, Genova
- Istituto Oncologico Veneto IRCCS-IOV, Padova
- Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture
- Istituto Nazionale Tumori Regina Elena, Roma
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [IRST]-IRCCS, Meldola-Forlì
- European School of Oncology (ESO), Milan
- IFOM - FIRC Institute of Molecular Oncology, Milan
- Ospedale San Raffaele (OSR), Milan
- Ente Ospedaliero Ospedali Galliera, Genova
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan
- Nerviano Medical Sciences Group S.r.l., Nerviano
Lithuania
★ National Cancer Institute, Vilnus

Norway
★ Oslo Universitetssykehus (OUS), Norway

Poland
• Wielkopolskie Centrum Onkologii, Poznan

Portugal
★ Instituto Português de Oncologia de Coimbra FG, EPE, Coimbra
★ Instituto Português de Oncologia de Lisboa FG, EPE, Lisbon
★ Instituto Português de Oncologia o Porto FG, EPE, Porto

Romania
★ The “Prof. Dr. Ion Chiricuta” Institute of Oncology (IOCN), Cluj
• SC RTC Radiology Therapeutic Center – Amethyst Radiotherapy, Otopeni

Russia
• Tatarstan Cancer Center “TCC”, Kazan
• N.N. Blokhin Russian Cancer Research Centre, Moscow
• P.A. Herzen Moscow Cancer Research Institute, Moscow

Serbia
• Institute of Oncology (IOV) Sremska Kamenica Novi Sad, Sremska Kamenica

Slovakia
• Ústav experimentálnej onkológie SAV, Bratislava

Slovenia
• Onkološki inštitut Ljubljana, Ljubljana

Spain
★ Fundación Instituto Valenciano de Oncología IVO Foundation, Valencia

★ Institut Català d’Oncologia, Barcelona
★ Instituto Madrileño de Oncología (Grupo IMO), Madrid

Sweden
• Karolinska Institutet, Stockholm

The Netherlands
★ Netherlands Cancer Institute, Amsterdam
• Maastricht University Medical Centre, Maastricht
• Radboudumc Centrum voor Oncologie, Nijmegen
• IKNL Integraal Kankercentrum Nederland, Utrecht
• Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam

Turkey
• Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Izmir

Ukraine
• RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR), Kyiv

United Kingdom
★ Cambridge Cancer Centre, Cambridge
★ The Christie NHS Foundation Trust, Manchester
★ King’s Health Partners Integrated Cancer Centre, London
• Cancer Research UK Glasgow Centre, Glasgow
• Imperial College Healthcare NHS Trust, London

Non-OECI Members in the A&D process
★ AZGroeninge Kortrijk, Belgium
★ Vejle Cancer Hospital, Denmark
★ Anadolu Medical Centre, Kocaeli, Turkey
DESCRIPTION OF THE INSTITUTE
The Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto) opened in April 1974, as a unit of the Public Sector and became a Corporate Public Entity with an annual service contract with the Minister of Health.
Moreover, it is the top line reference unit in oncology care in the North of Portugal, to where all the most complex cases are transferred to, with about 3.7 million of habitants to serve.

MISSION
The main mission is to render high quality, humanist and efficient oncology health care to the population. It is also part of the mission to develop research, training and teaching activities within oncology.

GENERAL ORGANIZATIONAL PRINCIPLES
1. The oncologic patient is the centre around which all care activity is built. For this reason all human and technical means available must be organized in a way as to give personalized, homogenous and holistic care.
2. Multidisciplinarity is assumed as the approach of the neoplastic disease, capable of offering an integrated and sequential treatment, in accordance with the highest scientific standards.
3. To achieve these goals, multidisciplinary units are created for each pathology, named Pathology Clinics, as the basis of the whole care structure.
QUALITY
It is the first Comprehensive Cancer Centre in Europe accredited by OECI (Organisation of European Cancer Institutes) since 2011, and Jacie for transplantation and cell therapy.

RESEARCH
Basic Research; Translational Research; Clinical Research; Epidemiologic Research;
The Portuguese Oncology Institute - Porto Research Center (CHPOP), hosted by IPO-Porto, is recognized by the Portuguese Science Foundation as an R&D unit. IPO-Porto has a consortium with IPATIMUP, which together comprises 15 translational research groups and a Clinical Trials Unit. The IPO-Porto/IPATIMUP consortium ensures a significant critical mass of investigators that allows fulfillment of the strategic institutional vision of having research as an integral part of patient care. The long-term objective of the IPO-Porto/IPATIMUP consortium is the understanding of the pathobiological mechanisms involved in carcinogenesis and in therapy response/resistance, which ultimately will help improve cancer prevention and/or treatment.
The Clinical Research Unit, which aims to collaborate in the development of more efficient therapies of cancer by participating in multicentric, carefully designed clinical trials. The unit supports all clinical departments of IPO-Porto in their participation in investigator initiated or international clinical trials, namely those promoted by EORTC, collaborative groups, or the pharmaceutical industry.

TEACHING
The main goal of the Department of Education (EPOP) is to promote continuous education in Oncology, providing state of the art transfer of knowledge to all professionals of IPO-Porto, as well as affiliated institutions and students or professionals from partner academic or health institutions. The department provides resources and facilities (+ 2.000m2) according to the educational needs identified every year which are materialized as the institutional continuous education plan.
All issues in oncology: Under-graduate Medical Training; Post-graduate Medical Training; Training for other Health Care Professionals; Training for the community.
Cancer is one of the major health issues affecting our society and is predicted to significantly increase globally as the population ages. Cancer diseases are expected to increase in the forty countries of Europe from 3.6 million cases in 2015 to 4.3 million cases in 2035, an increase of around 20%, translating to 716,000 additional cases each year. While cancer is already considered as a major chronic disease, the number of patients living with cancer is predicted to escalate from 28 to 82 million globally for the same timeline. Trends are similar in Europe, where in 2006 cancer caused 1.7 million deaths, an equivalent of three deaths/minute. This will cause the health care system to suffer a substantial extra demand, including required surveillance and recurrent treatment of both the disease and observed complications. Europe has no clear strategy to meet the increasing cancer burden, but it has a number of resources and expertise for developing the necessary translational cancer research. Both fragmentation and lack of sustainability are among the major obstacles to research collaboration in Europe and there is an urgent need for improving cooperation between basic/preclinical and comprehensive cancer centres, institutions in which care and prevention are integrated with research and education.

In response to the above challenges, the EurocanPlatform - a unique collaboration between 28 European Cancer Institutions and Organisations - targets the whole cancer research continuum from bench to bedside (basic, early and late translational, clinical, epidemiological, implementation in care, and population-based outcomes research) in an effort to improve cancer patient outcomes and reduce mortality. To achieve its objectives, the Platform focuses on three key research areas: prevention, early detection and therapeutics while also seeking to develop long-term sustainable strategies in each area.

By strengthening the integration between the different disciplines and stakeholders, the platform with its interlinked cancer centres, common infrastructures, and collaborative projects, is in a unique position to structure translational cancer research in Europe and to speed up the translation of discoveries into applications that impact patient lives. The consortia has access to large numbers of clinical samples, infrastructures e.g. biobanks with clinical information, bioinformatics, technology platforms, new and standardized technologies, as well as clinical trial units, which are all prerequisites for successful innovation and for meeting the demands of cancer therapeutics.

The EurocanPlatform prioritizes structuring actions as well as collaborative projects that facilitate rapid advances in knowledge and their translation into better cancer care, promotes education, training and mobility of young researchers in the area translational research, and disseminates information to society at large.
Counting 7 Partners, 11 Pilot Sites and the European Cancer Patients Coalition, under the coordination of the OECI, the Bench-Can project aims to improve quality of cancer patient’s treatment.

With an ageing population, the burden that cancer will impose on our society is likely to increase. Cancer has replaced cardiovascular diseases as the leading cause of premature death in 28 out of 53 European countries, becoming the leading cause of death. In this framework, and in the light of an highly affecting cost-benefit analysis, the Bench-Can project focuses on identifying how European providers can be assisted in order to improve services to the patients, reduce care provision inequalities, and raise a better quality of oncologic services.

The partnership of the project challenges two key topics:
1. ensuring an active engagement of European comprehensive cancer centres, clinical centres, cancer departments and units;
2. sustain the quality of treatments and outcomes of the operating environments for health services which have to adapt to co-morbidities of an ageing population, speed the technology development and related financial constraint, and reduce differences in health systems performances within EU countries.

The 11 Bench-Can Pilot Sites help to define:
– the description of a cancer care organisation using an agreed number of indicator sets describing the comprehensive care context;
– the modeling performance of comprehensive cancer centres or cancer departments/units at general hospitals, by several matrices (e.g. organizational objectives/intermediaries; staff/teams; intermediaries/services; services/patient outcome enablers; translational research or medicine-related data).

Detail analyses will be performed on all Pilot Sites, for instance using data envelopment techniques and, in particular, visiting the centres with a restricted group of specialists in order to define and refine a final Benchmarking Tool that focuses on operations management and best clinical practices and which will be available and applied to all interested Institutes/hospitals in Europe.

The expected Bench-Can final outcomes are:
(i) two benchmark tools planned for use in comprehensive cancer centres & cancer departments/units at general hospitals;
(ii) the identification of areas for improvement for quality of care & patient outcomes with advanced plans adopted by the pilot sites, at first, and by a broader audience in the coming years;
(iii) a benchmark manual with budget impact formulae for free access so to permit betterments in the management of cancer centres;
(iv) a roadmap for future assessments of comprehensive cancer care.

At the end of the project, we expect the Bench-Can tools to be adopted as a non-profit service available to cancer centres and services across the EU.
OECI 2015 ONCOLOGY DAYS

The OECI 2015 Oncology Days

June 22nd Morning
• Extended Board Meeting

June 22nd Afternoon
• Interim Meeting Bench-Can Project

June 22nd - 23rd
• OECI Pathology Day: Tumour Heterogeneity and Next Generation Sequencing - Morphology and Technology
  
June 22nd Afternoon Session
• Introduction and Clonal Heterogeneity

June 23rd Morning Session
• Heterogeneity and Phenotypic Plasticity
• Pharma Round Table

June 23rd Afternoon Session
• Round Table: Common aspects and diversities of tumour heterogeneity
• Round Table: Clinical biobanks and tumour heterogeneity

June 23rd
• OECI Core Activities Sessions
  
  Morning
Session 1: Role and organisation of a European Cancer Network: debating comprehensiveness
Session 2: The pillars for certification and designation of comprehensiveness

  Afternoon
Session 3: Partnership with industry
Session 4: Health Economics in Oncology: connecting theory to clinical practice in cancer centers

June 24th 8,30-13,00
• OECI General Assembly 2015

Social event
June 23rd Evening
• OECI 2015 Dinner Party
  Saint John's Day (Porto traditional celebration)
  Dress code - casual
  (restricted to OECI members and invited participants)
The aim is to share information about project results by focusing on practical knowledge with the objectives to:

• summarize findings, what we learned so far, their implications
• discuss whether it is useful for the participants who will ideally represent the project target groups
• discuss what are their needs, whether these are met by the project,
• discuss the experiences of the participants, the issues that are bothering them.

Targeted groups

• Representatives of the participating pilot sites;
• OECI members and Eurocan Platform partners;
• European stakeholders;
• Patient group representatives.

Programme

Chairman: Wim van Harten

14.00-14.10 Welcome, aim of the workshop
Wim van Harten

14.10-14.40 Benchmarking in comprehensive cancer care
Ellen Nolte

14.40-15.20 Bench-Can: Developing benchmarking tools
(introducing the tool)
14.40-15.00 BenchCan Qualitative tool
Anke Wind
15.00-15.20 BenchCan Quantitative tool
Isabelle Nefkens

15.20-15.50 Coffee Break

15.50-16.30 Experiences of the Pilot Sites
15.50-16.10 The CRO-Aviano experience within the benchmarking process during the Pilot Sites visit
Paolo De Paoli
16.10-16.30 The National Cancer Institute experience within the benchmarking process during the Pilot Sites visit
Ernestas Janulionis

16.30-16.50 Patient's voice in benchmarking cancer care
Pietro Presti

16.50-17.20 Identifying best practices, methodology and pilot proposal
Anke Wind and Peter Nagy

17.20-17.45 Moderated discussion with the audience

17.45-18.00 Summary of main discussion and action points and closing
OECI2015 ONCOLOGY DAYS

OECI Pathology Days
Tumour Heterogeneity and Next Generation sequencing: Morphology and Technology

Introduction and Clonal Heterogeneity
Chairs: Fatima Carneiro and Rui Henrique

14.30-14.45 Introduction

14.45-15.15 Why study tumour heterogeneity from a practical point of view in diagnostic and clinical research?
Giorgio Stanta

15.15-16.00 Can heterogeneity affect predictive biomarker diagnosis?
Marco Gerlinger

16.00-16.30 How can heterogeneity modify cancer diagnostics?
Manfred Dietel

16.30-17.00 Coffee Break

17.00-17.30 Colorectal cancer molecular subtypes: from patients to preclinical models and back. The problem of heterogeneity
Enzo Medico

17.30-18.00 NGS, clonal heterogeneity and cancer diagnostics
Gerald Hoefler

18.00-18.30 Can heterogeneity be studied in liquid biopsies?
Vera Kloten
OECI Pathology Days
Tumour Heterogeneity and Next Generation sequencing Morphology and Technology

Phenotypic Heterogeneity
Chairs: Manfred Dietel and Gerald Hoefler

09.00-09.20  Morphological and immunohistochemical heterogeneity in soft tissue neoplasia: diagnostic challenges
Mariana Afonso

09.20-09.40  Molecular heterogeneity of prostate carcinomas
Manuel Teixeira

09.40-10.00  Can phenotypic heterogeneity be fuelled by exosomes?
Sónia Melo

10.00-10.20  Molecular heterogeneity in premalignant lesions: is it clinically relevant?
José Carlos Machado

10.20-10.50  Coffee Break

Round Table

10.50-13.00  Industry, the point of view on Heterogeneity
Chairs: David Henderson and Kurt Zatloukal

Participants: David Henderson
Heterogeneity and treatment efficacy
Guido Henning
Standardized DNA and RNA extraction from FFPE Tumor tissue and impact of TCC (tissue heterogeneity) on expression profiling
Hannes Arnold
Resolving tumor heterogeneity in solid FFPE samples by DEPArray digital sorting
Pasquale De Blasio
TMA as tumour heterogeneity study instrument

13.00-14.00  Lunch
**Phenotypic Heterogeneity**

**Round Table**
14.00-16.00

*Common aspects and diversities of Tumour Heterogeneity, is a standardization possible?*

Chairs: Fred Bosman and Giorgio Stanta

Participants:
Anna Sapino
Breast
Cord Langner
Gastroenteric Tract
Lina Carvalho
Lung
Arndt Hartmann
Uropathology
Maria Rosaria Raspollini
Gynecological pathology
Isabel Fonseca
Head and neck

16.00-16.30
Coffee Break

**Round Table**
16.30-18.30

*Clinical Biobanks, how to tackle Heterogeneity*

Chairs: Jan-Eric Litton and Marialuisa Lavitrano

Participants:
Peter Riegman
Heterogeneity in clinical research
Kurt Zatloukal
Sampling strategy and quality requirements to address tumor heterogeneity in biobanking
Caroline Heckman
Heterogeneity in hematological disease: Challenges and solutions for NGS-based analyses
Ulf Landegren
Tumour heterogeneity studied at the protein level
Stefan Willems
Heterogeneity in molecular data reporting: how to get rid of that
General Session
OECI core activities

Morning Session Part 1
Role and organisation of a European Cancer Network: debating comprehensiveness
Chairs: Dominique de Valeriola

Welcome: the OECI vision of comprehensiveness in networks
Dominique de Valeriola

The European Quality Network and the Reference Network for Rare Cancers
Gemma Gatta

Cancer Core Europe: a platform to start meaningful European co-operation
Carlos Caldas

Organisation of cancer research and care at the P.A. Herzen Federal Cancer Centre, and collaborations with other centres
Andrey Kaprin

The expectation of patient’s association about CCNetwork
Francesco De Lorenzo

Discussion

Morning Session Part 2
The pillars for certification and designation of comprehensiveness
Chairs: José Laranja Pontes

Revised OECI standards for certification and designation
Mahasti Saghatchian

The OECI re-accreditation procedure
Femke Boomsma

The role of the A&D Auditors
Paolo De Paoli

The experience of an OECI Member certified as Comprehensive Cancer Centre
Petri Bono

The experience of an OECI Member certified as Clinical Cancer Centre
Ernestas Janulionis

How to improve the process: suggestions from the audience
Open Floor
General Session
OECI core activities

Afternoon Session Part 1
Partnership with industry
Chairs: Gunnar Sæter

The changing face of drug development and role of Comprehensive Cancer Centres
Gunnar Sæter

Benchmarking comprehensive cancer care: potential role in partnership with industry
Wim van Harten

Collaboration with industry: The experience of AACI
George Weiner

Relationship with a pharma research company: a challenge for the Academia
Marco Pierotti

Discussion

Afternoon Session Part 2
Health Economics in Oncology: connecting theory to clinical practice in cancer centers
Chairs: Wim van Harten

Case Report on health economic analysis in a cancer centre
Guy Storme

Clinical and Business Impact of Integrated practice units in Porto
Francisco Rocha- Goncalves

Business impact of return to work interventions for Cancer survivors and financial impact in seven EU countries
Janne Mewes

HTArget model, a health economics approach to evaluate targeted treatment over different tumor types
Valesca Retel

Discussion

Closing
General Assembly

08.00 Registration

08.15 General Assembly Constitution, welcome and approval of the Agenda
Chairperson: Dominique de Valeriola

08.30 Session 1: Administrative and financial matters
Chairperson: Dominique de Valeriola

Point 1: Approval of May 2014 General Assembly’s Minutes
(vote requested - decision taken at the simple majority of the OECI Full Members present or represented)
Dominique de Valeriola

Point 2: Approval of the Financial Statement 2014
(vote requested - decision taken at simple majority of the OECI Full Members present or represented)
Marco Pierotti

Point 3: 2015 and 2016 Provisional Budget
(only for 2015 budget the vote is requested – decision taken at simple majority of the OECI Full Members present of represented)
José Laranja Pontes

Point 4: OECI Board composition 2014-2017 update
(vote non requested)
Dominique de Valeriola

Point 5: Working Groups and Co-opted Board Members update
(vote not requested)
Dominique de Valeriola

Point 6: Modification of Art. 6.4 of the OECI Statute and of the Art. 3.2 of the OECI Internal Regulation: Payment and Collection of the Membership Fees
(vote requested – decision taken at the simple majority of the OECI Full Members present or represented)
Dominique de Valeriola

Point 7: OECI Membership – Annexes to Point 7
Claudio Lombardo

7.1 New applications for membership
(vote requested for full membership, decision taken at unanimity of the OECI Full Members present or represented; for associated membership, by simple majority of the OECI Full Members present or represented)

7.2 Request of transition of two Members
(vote requested - decision taken at simple majority of the votes of the OECI full members present or represented)
7.3 Requests of 2 Members to be dismissed from the OECI membership (vote not requested)

7.4 Proposal for discontinuing from the membership of OECI Members (vote requested - decision taken at two-thirds majority of the OECI Full Members present or represented)

7.5 Request of an Associate Member to be exempted from the payment of the OECI 2015 membership fee (vote requested – simple majority)

Ceremony for the delivery of the OECI Accreditation Certificates 2015

Dominique de Valeriola and Mahasti Saghatchian

Tartu University Hospital - Tartu, Estonia
Istituto Tumori Giovanni Paolo II, IRCCS – Bari, Italy
Azienda Ospedaliera – Arcispedale Santa Maria Nuova IRCCS - Reggio Emilia, Italy
Centro di Riferimento Oncologico – Istituto Nazionale Tumori - Aviano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Azienda Ospedaliera Universitaria S. Martino-IST - Genoa, Italy
Istituto Oncologico Veneto – Padova, Italy

10.30 Coffee break

Session 2: The OECI Strategy and Working Groups Activities
Chairperson: Dominique de Valeriola

Point 8: OECI future strategies
Dominique de Valeriola

8.1 Accreditation & Designation Mahasti Saghatchian
8.2 Biobanks and Molecular Pathobiology Giorgio Stanta
8.3 BenchCan Project Wim H. van Harten
8.4 EurocanPlatform NoE – update Ulrik Ringborg
8.5 Palliative Care Massimo Costantini
8.6 Communication and dissemination Gordon Mc Vie

Point 9: Venues of the General Assemblies for the coming years and closure of the G.A.
Dominique de Valeriola

13.00 Lunch
Chairpersons and invited speakers

Mariana Afonso
Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, Portugal

Hannes Arnold
Silicon Biosystems, Italy

Petri Bono
Central Hospital Comprehensive Cancer Center, Finland

Femke Boomsma
IKNL - Netherlands Comprehensive Cancer Organisation, The Netherlands

Fred Bosman
University of Lausanne, Switzerland

Carlos Caldas
Cambridge Cancer Center, United Kingdom

Fatima Carneiro
Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, Portugal

Lina Carvalho
University of Coimbra, Portugal

Massimo Costantini
Azienda Ospedaliera Santa Maria Nuova IRCCS, Italy

Pasquale De Blasio
Isetet, Milano, Italy

Francesco De Lorenzo
European Cancer Patient Coalition, Brussels, Belgium

Paolo De Paoli
CRO Aviano, National Cancer Institute, Italy

Dominique de Valeriola
Jules Bordet Institute, Brussels, Belgium

Manfred Dietel
Charité Comprehensive Cancer Center Berlin, Germany

Isabel Fonseca
University of Lisbon, Portugal

Gemma Gatta
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy

Marco Gerlinger
Institute of Cancer Research, London, United Kingdom

Ivo Gut
Centro Nacional de Analisis Genomico (CNAG), Barcelona, Spain

Wim H. van Harten
Netherlands Cancer Institute, Amsterdam, The Netherlands

Arndt Hartmann
University Erlangen-Nürnberg, Erlangen, Germany

Caroline Heckman
University of Helsinki, Finland

David Henderson
Bayer HealthCare, Berlin, Germany

Guido Hennig
Siemens Healthcare Diagnostics Holding GmbH, Eschborn, Germany

Rui Henrique
Portuguese Oncology Institute Porto, Portugal

Gerald Hoeffer
Medical University of Graz, Austria

Andrey Kaprin
P.A. Herzen Moscow Cancer Research Institute, Russian Federation

Vera Kloten
Hospital of the RWTH Aachen University, Germany

Ulf Landegren
University of Uppsala, Sweden

Cord Langner
Medical University of Graz, Austria

Marialuisa Lavitrano
Bicocca University, Milan, Italy

Jan-Eric Litton
Karolinska Institut, Stockholm, Sweden

Claudio Lombardo
OECI, Belgium

José Carlos Machado
Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, Portugal

Gordon McVie
Istituto Europeo di Oncologia, Italy

Enzo Medico
Istituto per la Ricerca e la Cura del Cancro di Candido, Italy

Sonia Melo
Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, Portugal

Janne Mewes
University of Twente, The Netherlands

Peter Nagy
National Institute of Oncology, Budapest, Hungary

Isabelle Nefkens
Panaxea, Enschede, The Netherlands

Ellen Nolte
European Observatory on Health Systems and Policies

Uwe Oelmüller
Qiagen GmbH, Germany

Marco A. Pierotti
FIRC Institute of Molecular Oncology (IFOM), Italy

Josè Laranja Pontes
Portuguese Oncology Institute Porto, Portugal

Pietro Presti
European Cancer Patient Coalition, Brussels, Belgium

Maria Rosaria Raspollini
University of Florence, Italy

Valesca Retel
Netherlands Cancer Institute, Amsterdam, The Netherlands

Peter Riegman
Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Ulrik Ringborg
Karolinska Institut, Stockholm, Sweden

Francisco Rocha-Goncalves
Portuguese Oncology Institute Porto, Portugal

Gunnar Sæter
Oslo University Hospital, Norway

Mahasti Saghatghanian
Gustave Roussy, France

Ernestas Janulionis
Institute of Oncology, Vilnius University, Lithuania

Anna Sapino
University of Turin, Italy

Giorgio Stanta
Department of Medical Sciences, University of Trieste, Italy

Guy Storme
Brussels Cancer Centre, Belgium

Manuel Teixeira
Portuguese Oncology Institute Porto, Portugal

George Weiner
Holden Comprehensive Cancer Center, University of Iowa, USA

Stefan Willems
University of Utrecht, The Netherlands

Anke Wind
Netherlands Cancer Institute, Amsterdam, The Netherlands

Kurt Zatloukal
Medical University of Graz, Austria
<table>
<thead>
<tr>
<th>Date</th>
<th>Morning</th>
<th>Afternoon</th>
<th>Evening</th>
</tr>
</thead>
</table>
| 22 June 2015 | **Extended Board meeting**  
*Instituto Português de Oncologia do Porto (IPO-Porto)* | **OECI Core Activities Sessions**  
Session 1: Role and organisation of a European Cancer Network - debating comprehensiveness  
Session 2: The pillars for certification and designation of comprehensiveness  
Room - Auditório Azul / Blue Auditorium | **Social Dinner** |
|            |                                                                                       | *OECI Pathology Day*  
Tumour Heterogeneity and Next Generation sequencing  
Morphology and Technology  
Introduction and Clonal Heterogeneity  
Room - Auditório Principal / Main Auditorium |                                                                  |
| 23 June 2015 | **Lunch**                                                                 | **OECI Pathology Day**  
Tumour Heterogeneity and Next Generation sequencing  
Morphology and Technology  
Round Table: Tumour heterogeneity - common aspects and diversities  
Round Table: Tumour heterogeneity - clinical biobanks  
Room - Auditório Principal / Main Auditorium | **Departure of the Delegates** |
|            |                                                                                       | **OECI Core Activities Sessions**  
Session 3: Partnership with industry  
Session 4: Health Economics  
Room - Auditório Azul / Blue Auditorium | **Sightseeing tour (see programme)** |
| 24 June 2015 | **OECI 2014 General Assembly**  
Room - Auditório Principal / Main Auditorium | **Lunch**                                                                 | **Dinner Party** |

**General timetable**
Social events

**June 22nd**
20.00 hrs.

**BenchCan, Pathology Day and Board Dinner**
Bem Arranjadinho Restaurant

**June 23rd**

**Dinner Party**
20.00 hrs.
**OPO Restaurant**
(Restricted to OECI Members and invited people registration required)
The Oncology Days are organised in collaboration with:

IPO Porto

Eurocan Platform

BenchCan

BBMRI-ERIC

European Society of Pathology

The Oncology Days are co-financed by the European Commission through:

Eurocan Platform NoE “Health-F2-2010-260791”

BenchCan Project “Grant. Agreement 2012 12 11”
THE OECI 2015 SCIENTIFIC COMMITTEE
President: Dominique de Valeriola
Members: José Laranja Pontes, Carlos Caldas, Wim van Harten, Marco A. Pierotti, Peter Riegman, Ulrik Ringborg, Gunnar Sæter, Mahasti Saghatchian, Giorgio Stanta

THE OECI 2015 LOCAL SCIENTIFIC COMMITTEE
President: José Laranja Pontes
Members: Rosa Begonha, Maria Isabel Dias Sequeira, Francisco Nuno Rocha Gonçalves, Ilídio José Nunes de Oliveira Cadilhe

THE OECI 2015 LOCAL ORGANISING COMMITTEE
Mediana - Global Communication
Ph: +351 225 573 760
Email: geral@mediana.pt

THE OECI 2015 ONCOLOGY DAYS SECRETARIATS
BRUSSELS: Maria Cummins
GENOA: Germana Gianquinto, Giorgia Pesce, Patrizia Sommella
TRIESTE: Valentina Melita

OECI 2015 ONCOLOGY DAYS COORDINATING OFFICE
Claudio Lombardo - OECI Director
Tel: +32 2 512 01 46
Email: oeci@oeci.eu
www.oeci.eu

ecancermedicalscience
Official OECI Journal